Altimmune said pemvidutide's Phase III MASH trial has over 70 U.S. sites active, with 52-week data expected in 2029; an FDA meeting on AUD is scheduled for December, and RESTORE data are expected in the second half of 2027.
ALT · Altimmune, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.41
- Open
- $1.40
- Day range
- $1.38–1.45
- 52-week closing range
- $1.39–6.18
- Average volume, 30 days
- 3.9M
- Short interest
- 42.1M · 21.7% of shares · 12.2 days
- Short volume, last session
- 56%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Altimmune began enrolling patients in the global PERFORMA Phase 3 trial evaluating pemvidutide in MASH; the 52-week data readout to support accelerated approval is anticipated in 2029.
Altimmune reported $480 million in cash, cash equivalents and investments as of September 30, 2026, and a net loss of $31.6 million, or $0.15 per share. PERFORMA Phase 3 progressed as planned, and an FDA End-of-Phase 2 meeting for AUD was scheduled for December 2026.
Altimmune, Inc. drew $10.0 million after achieving clinical and financial milestones, extending its amortization date and interest-only period to June 1, 2028. The company must maintain qualified cash greater than or equal to 60% of outstanding term loan advances.
Altimmune's board appointed Peter Greenleaf and Alex Howarth as directors effective November 2, 2026, increasing its size from nine to eleven. John Gill, Mitchel Sayare and Klaus Schafer will retire from the board at the 2027 annual meeting.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Pemvidutide reported statistically significant AUD results and favorable MASH data, received key regulatory designations, and continued Phase 2 and Phase 3 development while cash runway extends through the expected 2029 PERFORMA readout. However, Q3 R&D, G&A and net loss increased year over year, AUD program timing remains unspecified, and development faces regulatory, manufacturing, enrollment and clinical execution risks.
- + The global PERFORMA Phase 3 trial is progressing as planned.
- + RECLAIM produced statistically significant improvements in heavy drinking days and key FDA-registrational secondary measures.
- + IMPACT showed concurrent improvements in liver fat, inflammation and fibrosis versus placebo.
- + Cash burn is tracking to plan, with operating runway through the expected 2029 PERFORMA readout.
- + An FDA end-of-Phase 2 meeting for the AUD Phase 3 program is scheduled for December 2026.
- − Q3 net loss increased to $31.6 million from $19.0 million year over year.
- − Q3 R&D expense increased to $27 million from $15 million year over year.
- − Q3 G&A expense increased to $8.7 million from $5.9 million year over year.
- − Timing for the AUD program remains unspecified pending regulatory feedback.
- − Development remains exposed to regulatory delays, manufacturing and supply-chain interruptions, site-access and enrollment risks, and clinical-trial execution risk.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALT
this stock
Altimmune, Inc.
|
$274.37M | -60.9% | +105.0% | — | 21.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 23
Altimmune began enrolling patients in the global PERFORMA Phase 3 trial evaluating pemvidutide in MASH; the 52-week data readout to support accelerated approval is anticipated in 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALT | -12.4% | -35.0% | -53.2% | -30.9% | -60.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -7.0% | -28.7% | -47.5% | -25.6% | -65.9% |